A lower psoas muscle volume was associated with a higher rate of recurrence in male clear cell renal cell carcinoma

Background Sarcopenia is defined as a low skeletal muscle volume. Recent studies have reported that sarcopenia is associated with a poor prognosis in various cancers. The purpose of this study is to evaluate the correlation between the psoas muscle volume and recurrence-free survival in patients with localized clear cell renal cell carcinoma (ccRCC). Methods A total of 316 male patients with localized ccRCC who underwent radical nephrectomy at Yokohama City University Hospital (Yokohama, JAPAN) and Kanagawa Cancer Center (Yokohama, JAPAN) between 2002 and 2018 were enrolled in this study. The psoas muscle index (PMI) was calculated by normalizing the psoas muscle area on the contralateral side of the tumor on axial CT, which was calculated at the level of L4 (mm2) divided by the square of the body height (m2). We divided patients into two groups based on the median PMI (409.64mm2/m2). Results The lower PMI group showed poorer recurrence-free survival (RFS) than the higher PMI group (p = 0.030). Regarding 5-year RFS, a lower PMI was a significant predictor of recurrence (p = 0.022, hazard ratio (HR): 2.306) and a multivariate analysis revealed that a lower PMI (4 cm (p = 0.044, HR: 2.341), and pathological stage >2 (p<0.001, HR: 3.660) were independent risk factors for poor RFS. Conclusions The presence of sarcopenia (lower PMI) was found to be associated with poor RFS in male ccRCC patients. The PMI might serve as a measure of patient frailty and might be useful for prognostic risk stratification in ccRCC.

[1]  M. Yao,et al.  A low psoas muscle volume correlates with a longer hospitalization after radical cystectomy , 2017, BMC Urology.

[2]  Thomas A. Jackson,et al.  Frailty and sarcopenia: The potential role of an aged immune system , 2017, Ageing Research Reviews.

[3]  J. Cheville,et al.  Decreased Skeletal Muscle Mass is Associated with an Increased Risk of Mortality after Radical Nephrectomy for Localized Renal Cell Cancer. , 2016, The Journal of urology.

[4]  J. Mezhir,et al.  The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature , 2015, Journal of surgical oncology.

[5]  M. Mizumoto,et al.  Impact of preoperative quality as well as quantity of skeletal muscle on survival after resection of pancreatic cancer. , 2015, Surgery.

[6]  Y. Sakamoto,et al.  Sarcopenia is a Negative Prognostic Factor After Curative Resection of Colorectal Cancer , 2015, Annals of Surgical Oncology.

[7]  T. Yamanaka,et al.  Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma , 2013, The British journal of surgery.

[8]  Michael J. Englesbe,et al.  Sarcopenia as a Prognostic Factor among Patients with Stage III Melanoma , 2011, Annals of Surgical Oncology.

[9]  J. Baeyens,et al.  Sarcopenia: European consensus on definition and diagnosis , 2010, Age and ageing.

[10]  J. Lam,et al.  Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system. , 2005, The Journal of urology.

[11]  J. Cheville,et al.  Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma , 2003, Cancer.

[12]  J. Cheville,et al.  An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. , 2002, The Journal of urology.

[13]  R. Figlin,et al.  Improved prognostication of renal cell carcinoma using an integrated staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Moch,et al.  Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma , 2000, Cancer.